33,300 Shares in BioTelemetry Inc (NASDAQ:BEAT) Bought by APG Asset Management N.V.

APG Asset Management N.V. purchased a new stake in shares of BioTelemetry Inc (NASDAQ:BEAT) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 33,300 shares of the medical research company’s stock, valued at approximately $1,857,000. APG Asset Management N.V. owned 0.10% of BioTelemetry as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Mark Sheptoff Financial Planning LLC boosted its stake in shares of BioTelemetry by 13.3% in the fourth quarter. Mark Sheptoff Financial Planning LLC now owns 1,700 shares of the medical research company’s stock worth $79,000 after acquiring an additional 200 shares during the period. Mutual of America Capital Management LLC boosted its stake in BioTelemetry by 21.8% in the 1st quarter. Mutual of America Capital Management LLC now owns 1,477 shares of the medical research company’s stock worth $57,000 after purchasing an additional 264 shares during the period. Mason Street Advisors LLC grew its holdings in BioTelemetry by 2.9% during the 4th quarter. Mason Street Advisors LLC now owns 11,839 shares of the medical research company’s stock valued at $548,000 after buying an additional 332 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of BioTelemetry by 0.4% during the first quarter. New York State Common Retirement Fund now owns 90,418 shares of the medical research company’s stock valued at $3,482,000 after buying an additional 404 shares during the last quarter. Finally, Amalgamated Bank lifted its holdings in shares of BioTelemetry by 7.2% in the fourth quarter. Amalgamated Bank now owns 6,634 shares of the medical research company’s stock worth $307,000 after buying an additional 444 shares in the last quarter. Institutional investors and hedge funds own 94.64% of the company’s stock.

A number of research analysts have recently weighed in on the company. ValuEngine lowered BioTelemetry from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Zacks Investment Research lowered BioTelemetry from a “hold” rating to a “sell” rating in a research report on Monday, May 11th. BidaskClub downgraded BioTelemetry from a “buy” rating to a “hold” rating in a research report on Friday, June 12th. Finally, Benchmark decreased their price target on BioTelemetry from $82.00 to $55.00 and set a “buy” rating on the stock in a report on Thursday, March 19th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $61.50.

BEAT opened at $45.19 on Wednesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 4.19 and a current ratio of 4.34. The stock’s 50 day moving average price is $45.93 and its 200-day moving average price is $45.58. BioTelemetry Inc has a one year low of $27.35 and a one year high of $55.85. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of 22.42, a P/E/G ratio of 2.97 and a beta of 1.32.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.45 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.02. BioTelemetry had a return on equity of 19.94% and a net margin of 5.64%. The company had revenue of $113.03 million during the quarter, compared to analysts’ expectations of $112.90 million. During the same quarter in the previous year, the business earned $0.42 EPS. BioTelemetry’s revenue was up 8.7% compared to the same quarter last year. As a group, analysts predict that BioTelemetry Inc will post 1.49 earnings per share for the current fiscal year.

BioTelemetry Profile

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

Recommended Story: How to interpret Moving Average Convergence Divergence (MACD)

Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry Inc (NASDAQ:BEAT).

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.